Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients.

ABSTRACT: PURPOSE:Late-life depression even in subsyndromal stages is strongly associated with Alzheimer's disease (AD). Furthermore, brain amyloidosis is an early biomarker in subjects who subsequently suffer from AD and can be sensitively detected by amyloid PET. Therefore, we aimed to compare amyloid load and glucose metabolism in subsyndromally depressed subjects with mild cognitive impairment (MCI). METHODS:[(18)F]AV45 PET, [(18)F]FDG PET and MRI were performed in 371 MCI subjects from the Alzheimer's Disease Neuroimaging Initiative Subjects were judged ?-amyloid-positive (A?+; 206 patients) or ?-amyloid-negative (A?-; 165 patients) according to [(18)F]AV45 PET. Depressive symptoms were assessed by the Neuropsychiatric Inventory Questionnaire depression item 4. Subjects with depressive symptoms (65 A?+, 41 A?-) were compared with their nondepressed counterparts. Conversion rates to AD were analysed (mean follow-up time 21.5?±?9.1 months) with regard to coexisting depressive symptoms and brain amyloid load. RESULTS:A?+ depressed subjects showed large clusters with a higher amyloid load in the frontotemporal and insular cortices (p?

SUBMITTER: Brendel M 

PROVIDER: S-EPMC5849231 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature